ARNI Transition in Heart Failure
On this page
Direct answer
Switching an ACE inhibitor to sacubitril/valsartan demands a 36-hour washout between the last ACE inhibitor dose and the first ARNI dose — the interval that prevents simultaneous neprilysin and ACE inhibition from piling unopposed bradykinin into angioedema. PARADIGM-HF, stopped early for benefit, showed a 20 per cent reduction in cardiovascular death or heart failure hospitalisation versus enalapril in symptomatic chronic HFrEF, making ARNI a cornerstone rather than an add-on. Start 49/51 mg twice daily (24/26 mg if switching from low-dose ACE inhibition, elderly or naive), titrate to the 97/103 mg target by doubling every 2-4 weeks as tolerated. Contraindications are a history of any angioedema, concurrent ACE inhibitor or aliskiren, and pregnancy; monitor potassium, creatinine and systolic pressure at each step exactly as for any RAAS blocker.
What you must remember
- The number examiners want: 36-hour washout — never overlap ACE inhibitor and ARNI, never combine them.
- Doses: sacubitril/valsartan 49/51 mg twice daily starting (24/26 mg in low-dose switch, hypotension-prone or ACE-naive patients), target 97/103 mg twice daily.
- PARADIGM-HF: 20 per cent reduction in the composite of cardiovascular death and heart failure hospitalisation versus enalapril 10 mg twice daily; symptomatic HFrEF patients.
- PIONEER-HF: in-hospital initiation after stabilisation is safe and effective — do not wait weeks after an admission.
- Mechanism: sacubitril inhibits neprilysin (natriuretic peptides, bradykinin, adrenomedullin and other substrates persist), valsartan blocks AT1 receptors — natriuresis and vasodilation with RAAS blockade.
- Contraindications and cautions: prior angioedema (any cause), pregnancy, bilateral renal artery stenosis, potassium above 5.4 mmol/L, eGFR under 30 mL/min and systolic pressure under 100 mmHg require judgement before initiation or up-titration.
- Indian context: generic sacubitril-valsartan has made the switch affordable across teaching hospitals, though it remains outside the National List of Essential Medicines; the practical barrier is remembering the washout when pharmacists substitute brands.
Executing the switch on a ward round
Take a 56-year-old with an ejection fraction of 30 per cent, NYHA class II on ramipril 10 mg, bisoprolol 10 mg and spironolactone 25 mg, still breathless on stairs. The decision to switch is guideline-automatic for symptomatic HFrEF on an ACE inhibitor. Order the last ramipril dose at 8 pm on Monday; first ARNI dose at 8 am Wednesday — 36 hours. Choose 49/51 mg twice daily because his ramipril dose was high. Check blood pressure, potassium and creatinine at 1-2 weeks, double to 97/103 mg twice daily if systolic pressure holds above 100 and potassium below 5.4. Warn him about symptomatic hypotension on standing in week one. If he had instead been ARB-experienced (losartan 100 mg), no washout is needed — switch directly at an equivalent-intensity starting dose, because ARB plus neprilysin inhibition was PARADIGM's own comparator arm's safety profile in practice.
The switch does not replace anything else: beta-blocker, mineralocorticoid antagonist and SGLT2 inhibitor layers continue, and ivabradine or devices follow their own triggers.
Where the switch goes wrong
The dangerous error is arithmetic on the washout: 36 hours means a day and a half, not "next dose"; and the error's mirror image is pharmacists or cross-cover teams starting an ACE inhibitor on top of an existing ARNI prescription, which is why the drug chart must show one agent discontinued in ink. Second, angioedema history: any prior angioedema — including hereditary or aspirin-related — contraindicates ARNI, since bradykinin accumulation is the shared final pathway; examiners pair this with the viva question on why ARNI angioedema risk is low in practice yet non-zero. Third, titration timidity: many Indian prescriptions fossilise at 49/51 mg when the target is 97/103 mg — under-dosing a proven therapy out of hypotension fear, when the correct move is check volume status, reassess timing, then titrate. A final exam pearl: neprilysin also degrades amyloid beta, and theoretical Alzheimer concerns have not translated into clinical trial signals — quotable as reasoned reassurance.
Frequently asked questions
Why is a 36-hour washout required before starting sacubitril/valsartan?
Overlap of ACE inhibition and neprilysin inhibition causes unopposed bradykinin accumulation and angioedema risk.
What starting dose is used when transitioning from an ACE inhibitor?
49/51 mg twice daily for most, or 24/26 mg twice daily after low-dose ACE inhibition, in the elderly, or in previously untreated patients.
What did PARADIGM-HF demonstrate?
A 20 per cent reduction in cardiovascular death and heart failure hospitalisation versus enalapril, leading to early trial termination for benefit.
Can ARNI be initiated during a heart failure admission?
Yes — PIONEER-HF supported in-hospital initiation once the patient is stabilised, with monitoring of blood pressure, renal function and potassium.
Which patients should not receive ARNI at all?
Those with any history of angioedema, pregnancy, or concurrent ACE inhibitor or aliskiren therapy.